Cargando…
Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic revi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617735/ https://www.ncbi.nlm.nih.gov/pubmed/34835261 http://dx.doi.org/10.3390/vaccines9111330 |
_version_ | 1784604577650180096 |
---|---|
author | Rosamilia, Francesca Noberasco, Giovanni Olobardi, Dario Orsi, Andrea Icardi, Giancarlo Lantieri, Francesca Murdaca, Giuseppe |
author_facet | Rosamilia, Francesca Noberasco, Giovanni Olobardi, Dario Orsi, Andrea Icardi, Giancarlo Lantieri, Francesca Murdaca, Giuseppe |
author_sort | Rosamilia, Francesca |
collection | PubMed |
description | Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage. |
format | Online Article Text |
id | pubmed-8617735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86177352021-11-27 Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review Rosamilia, Francesca Noberasco, Giovanni Olobardi, Dario Orsi, Andrea Icardi, Giancarlo Lantieri, Francesca Murdaca, Giuseppe Vaccines (Basel) Systematic Review Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage. MDPI 2021-11-15 /pmc/articles/PMC8617735/ /pubmed/34835261 http://dx.doi.org/10.3390/vaccines9111330 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Rosamilia, Francesca Noberasco, Giovanni Olobardi, Dario Orsi, Andrea Icardi, Giancarlo Lantieri, Francesca Murdaca, Giuseppe Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review |
title | Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review |
title_full | Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review |
title_fullStr | Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review |
title_full_unstemmed | Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review |
title_short | Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review |
title_sort | flu and pneumococcal vaccine coverage in scleroderma patients still need to be prompted: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617735/ https://www.ncbi.nlm.nih.gov/pubmed/34835261 http://dx.doi.org/10.3390/vaccines9111330 |
work_keys_str_mv | AT rosamiliafrancesca fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT noberascogiovanni fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT olobardidario fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT orsiandrea fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT icardigiancarlo fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT lantierifrancesca fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT murdacagiuseppe fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview |